The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the WntΒ-catenin pathway

Abstract

The development of chemoresistance represents a major obstacle in the successful treatment of cancers such as neuroblastoma (NB), a particularly aggressive childhood solid tumour. The mechanisms underlying the chemoresistant phenotype in NB were addressed by gene expression profiling of two doxorubicin (DoxR)-resistant vs sensitive parental cell lines. Not surprisingly, the MDR1 gene was included in the identified upregulated genes, although the highest overexpressed transcript in both cell lines was the frizzled-1 Wnt receptor (FZD1) gene, an essential component of the WntΒ-catenin pathway. FZD1 upregulation in resistant variants was shown to mediate sustained activation of the WntΒ-catenin pathway as revealed by nuclear Β-catenin translocation and target genes transactivation. Interestingly, specific micro-adapted short hairpin RNA (shRNAmir)-mediated FZD1 silencing induced parallel strong decrease in the expression of MDR1, another Β-catenin target gene, revealing a complex, WntΒ-catenin-mediated implication of FZD1 in chemoresistance. The significant restoration of drug sensitivity in FZD1-silenced cells confirmed the FZD1-associated chemoresistance. RNA samples from 21 patient tumours (diagnosis and postchemotherapy), showed a highly significant FZD1 andor MDR1 overexpression after treatment, underlining a role for FZD1-mediated WntΒ-catenin pathway in clinical chemoresistance. Our data represent the first implication of the WntΒ-catenin pathway in NB chemoresistance and identify potential new targets to treat aggressive and resistant NB. © 2009 Macmillan Publishers Limited.